about
Amplicon Indel Hunter Is a Novel Bioinformatics Tool to Detect Large Somatic Insertion/Deletion Mutations in Amplicon-Based Next-Generation Sequencing Data.Certification in molecular pathology in the United States: an update from the Association for Molecular Pathology Training and Education Committee.Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism.Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts.Ibrutinib resistance in chronic lymphocytic leukemiaRequirements for U2 snRNP addition to yeast pre-mRNA.JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapyAtypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myelomaHeightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinibSplenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition.The proapoptotic factors Bax and Bak regulate T Cell proliferation through control of endoplasmic reticulum Ca(2+) homeostasisMolecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation.Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.NK/T cell non-Hodgkin lymphoma in a HIV-positive patient.Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disordersJAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug.Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.Strongyloides stercoralis infection presenting as an unusual cause of massive upper gastrointestinal bleeding in an immunosuppressed patient: a case report.Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival.Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.Prognosis in Chronic Lymphocytic Leukemia-Reply.Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.Detection of BCL2-IGH using single-round PCR assays.JAK2 Mutations are present in all cases of polycythemia veraCerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed/refractory B-cell malignanciesActivation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphomaNovel bcl-2 breakpoints in patients with follicular lymphomaClonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLLXPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκBMetabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells
P50
Q30990644-2F4400DC-1189-40EE-BBA2-2F71E764C1F6Q34296241-B21B1424-6DA8-4DBB-BEBF-773D89287A6DQ35750111-1E521768-FB2A-4AB5-9DA6-BCAC3271E64DQ35790163-78DDFFB8-2F1B-439D-84F5-85FCFFA93315Q35881570-25943EA2-3D76-470A-B989-B0335DD72703Q35925510-7EEEED75-88BA-4977-9848-C0FB3D5574F4Q36765086-47392A13-439D-42BD-A197-EF1796B34653Q36766519-3E87634A-1694-482B-B102-0C65D53DEF01Q36782516-CDB814F1-A8E4-417D-B944-338A34B90304Q36784523-C397CA2C-B6F9-4D16-A2B3-2F0F6DB81645Q37271231-312C2205-B34A-43C9-A930-34E5A1BF114EQ38123300-DD45B7AE-49F5-495C-8E8D-CC8D48D37B26Q38548478-10BA405D-05F0-4C04-BC4E-87F84E7BF9AAQ38819065-1DF0F4DF-89F8-4C31-9EEA-02821385877EQ38959765-E5F026CB-8316-4839-AB18-7FFAAF7F553FQ39056302-F261A69A-34E5-4BFE-ABB6-AA504A1847B6Q39361184-3805076E-C3CA-48BD-B47A-0B71A3747A6BQ39965971-1852C6FA-B34D-4FDA-B40D-2ADBB224DD65Q40991862-07690C09-4F79-42C3-A1AB-CC1B8CBA4ACFQ41809583-0AFCBAB5-E5B9-4C68-ABEC-F283D36D5688Q42924727-55747AF6-C73E-4A9B-8110-AEC27C161FC1Q43196182-ADE36388-022B-4D2D-90A8-93184C0DB204Q43937435-C01BD821-430F-4DEF-A226-8B8B24808AD5Q44039974-C6DD7AB4-C060-4D09-A828-D670C889B715Q51072600-21BCF8B6-B44A-4D3C-BFBF-01A0D64CC2EBQ52911419-B1815845-9CC8-44BA-8B46-46AAFE66CEBAQ53042357-714046A9-35BC-433B-BCED-2F379C6D0FEBQ54680465-F5C7FDEB-ECC4-473A-93FD-AF1AA09FA252Q58455709-76997A86-34AD-4F6D-9A78-ED03B58115CAQ58605762-1761324F-F3DA-47CC-8F99-2DFB3211D059Q58773255-706D4D8C-2216-4B91-BBBE-48F5D21A8D20Q77452608-EA0D044B-1BBC-411E-B788-8FF33D231A14Q89776891-2F319A57-1A24-4DDC-86A1-48B360DE9227Q90227319-94821BDE-D0DA-4E58-8331-C093B83649F5Q92309727-4248672D-7C6B-4DFA-AB05-420E459282A5
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Y Wang
@ast
Y Wang
@en
Y Wang
@es
Y Wang
@nl
Y Wang
@sl
type
label
Y Wang
@ast
Y Wang
@en
Y Wang
@es
Y Wang
@nl
Y Wang
@sl
prefLabel
Y Wang
@ast
Y Wang
@en
Y Wang
@es
Y Wang
@nl
Y Wang
@sl
P106
P1153
35286128200
P31
P496
0000-0003-0773-1212